Mixed Data Cloud Future Of Sunovion's ADHD Drug

 
• By Lucie Ellis-Taitt

Sunovion's ADHD drug, dasotraline, has missed its primary endpoint in a Phase III study in adult patients but has reported mixed results in children, prompting the company to continue pursuing its 2017 plans for an FDA filing in both age groups. But data for the non-stimulant ADHD therapy suggest it will be tricky to overthrow market stalwarts.

Wooden dummy
Sunovion Will Target ADHD As Dasotraline's First Regulatory Filing • Source: Shutterstock

More from Clinical Trials

More from R&D